Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Long-acting ghrelin for neuropathy

Award Number: R43NS115312
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

Long-acting ghrelin for neuropathy - Project Summary Neuropathy is an acquired disease that can lead to debilitating chronic pain affecting 7% to 10% of the general population. Among patients with symptomatic neuropathy, sleep disturbances, anxiety and depression are common, negatively impacting quality of life. Diabetes is a leading cause of neuropathy and is expected to become more prevalent as the incidence of diabetes increases. Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of numerous common chemotherapeutics. Unfortunately, there are no disease modifying therapeutics that can prevent neuropathy or regenerate nerves. While there are palliative treatments for pain symptoms, they are effective in less than 50% of patients and use of opioids is restricted for the most severe cases of chronic pain as they can lead to addiction. Clearly there is a need for safe, effective, well- tolerated drugs to treat painful neuropathy by halting or reversing the underlying pathology of the disease. One promising approach to treating painful neuropathy without opioids is the use of ghrelin, a 28-amino acid acylated peptide hormone. However, it has a short half-life and must be delivered via a constant intravenous infusion to have a therapeutic effect. Extend Biosciences' D-VITylation platform technology is truly enabling for small peptide-based therapeutics that are rapidly cleared from the bloodstream by renal filtration. Our platform harnesses the naturally long half-life of vitamin D and its dedicated binding protein, VDBP. When our vitamin D molecule is conjugated to a biological therapeutic, it dramatically improves the half-life and bioavailability of the drug. In addition, use of the technology should also allow the drug to be self-administered by subcutaneous injection. This would be of significant benefit to patients. In our preliminary experiments, we applied D- VITylation to this promising peptide to generate EXT405 as a therapeutic for neuropathy. Pharmacokinetic data show an extended half-life compared to the native peptide. In this Phase I SBIR, we propose to test the efficacy of EXT405 in a cell-based model of neuropathy as well as in animal models of CIPN and diabetes- induced neuropathy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	EXTEND BIOSCIENCES INC.	90 BRIDGE ST SUITE 100	NEWTON	MA	02458	MIDDLESEX	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/14/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	EXTEND BIOSCIENCES INC.	90 BRIDGE ST SUITE 100	NEWTON	MA	02458	MIDDLESEX	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	10/14/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $535,325 )
2019	2019	EXTEND BIOSCIENCES INC.	90 BRIDGE ST SUITE 100	NEWTON	MA	02458	MIDDLESEX	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/18/2019	NEW	$535,325
														Subtotal = $535,325

Grand Total All Awards = $535,325

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Long-acting ghrelin for neuropathy

Award Number: R43NS115312

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer